Efficacy of delandistrogene moxeparvovec on Duchenne muscular dystrophy: a systematic review and meta-analysis
- 26 June 2025
- journal article
- review article
- Published by Springer Nature in Human Genetics
- Vol. 144 (8) , 795-807
Abstract
No abstract availableKeywords
Funding Information
- Universidad de Castilla-La Mancha
- Ministerio de Ciencia, Innovación y Universidades (FPU21/06866)
This publication has 48 references indexed in Scilit:
- Wie sicher ist die Gentherapie?Die Innere Medizin, 2024
- Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR)Annals of Neurology, 2023
- Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trialMuscle & Nerve, 2023
- A systematic review of pharmacologic therapies for the cardiomyopathy of Duchenne muscular dystrophyPediatric Pulmonology, 2021
- Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular DystrophyJAMA Neurology, 2020
- Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic reviewAnnals of Clinical and Translational Neurology, 2020
- Cochrane Handbook for Systematic Reviews of Interventions2019
- Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural historyMuscle & Nerve, 2018
- The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy MutationsHuman Mutation, 2015
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002